NEOVACS: patent filing in Europe and the United States for its new therapeutic vaccine candidate in allergies

      Comments Off on NEOVACS: patent filing in Europe and the United States for its new therapeutic vaccine candidate in allergies
<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = " PRESS RELEASE · PRESS RELEASE · PRESS RELEASE "data-reactid =" 11 "> PRESS RELEASE · PRESS RELEASE · PRESS RELEASE

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Neovacs announces the filing of a patent in Europe and the United States "data-reactid =" 12 ">Neovacs announces the filing of a patent in Europe and the United States

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "for its new Kinoid therapeutic vaccine candidate IL-4 / IL-13 "data-reactid =" 13 ">for its new Kinoid therapeutic vaccine candidate IL-4 / IL-13

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "in the treatment of allergies."data-reactid =" 14 ">in the treatment of allergies.

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Paris and Boston, November 20, 2018 – 5.45 pm CET- Néovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of autoimmune and inflammatory diseases, announces the filing of a patent following the obtaining of the preclinical proof of concept with its new IL-4 / IL-13 Kinoid vaccine in the treatment of asthma. "data-reactid =" 15 ">Paris and Boston, November 20, 2018 – 5.45 pm CET- Néovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of autoimmune and inflammatory diseases, announces the filing of a patent following the obtaining of the preclinical proof of concept with its new IL-4 / IL-13 Kinoid vaccine in the treatment asthma.

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The model of allergy used is based on the Sibilano works 1 because it presents the main symptoms of asthma in humans, namely inflammation and hyperreactivity of the airways. In this dust mite-sensitized asthma model, immunization with the IL-4 and IL-13 kinoid induces a strong production of antibodies that neutralize these two cytokines and reduces several major symptoms of asthma. "Data-reactid = "16"> Allergy model used is based on Sibilano's work 1 because it presents the main symptoms of asthma in humans, namely inflammation and hyperreactivity of the airways. In this dust mite-sensitized asthma model, immunization with kinoid IL-4 and IL-13 induces a high production of antibodies that neutralize these two cytokines and reduces several major symptoms of asthma.

This work led to the filing of a patent concerning the development of a new kinoid targeting these two crucial cytokines in the process of allergy in all its forms, be they respiratory, dermatological or food. On this basis, Néovacs will continue the preclinical development needed to conduct clinical trials in these conditions.

Neovacs announced in July 2018 the results of its phase 2b clinical study with IFNalpha Kinoide in the treatment of lupus validating its innovative therapeutic approach in humans and the continuation of clinical development in phase III.

The company is also pursuing the next steps of the ongoing preclinical program in type 1 diabetes with IFNalpha Kinoide.

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = " "data-reactid =" 20 ">

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "About Allergies "data-reactid =" 21 ">About Allergies

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Allergies are a major public health problem of which the prevalence is steadily increasing affecting more than 300 million people with asthma and between 200 and 250 million food allergies.One-tenth of the population suffers from drug allergies and 400 million rhinitis 2 . To date, there is no effective treatment over time for these diseases. The cytokines IL-4 and IL-13 play a key role in allergic reactions and represent major therapeutic targets. Most current treatments for allergies are symptomatic (mainly antihistamines and corticosteroids). The only therapeutic strategy developed to date is allergen-specific immunotherapy, which consists of administering increasing doses of an allergen over several months for desensitization. However, allergen-specific immunotherapy is limited by high levels of adverse reactions and poor long-term efficacy, especially for food allergies. "Data-reactid =" 22 "> Allergies are a major public health problem the prevalence of which is steadily increasing, affecting more than 300 million people with asthma and between 200 and 250 million food allergies One tenth of the population suffers from drug allergies and 400 million rhinitis 2 . To date, there is no effective treatment over time for these diseases. The cytokines IL-4 and IL-13 play a key role in allergic reactions and represent major therapeutic targets. Most current treatments for allergies are symptomatic (mainly antihistamines and corticosteroids). The only therapeutic strategy developed to date is allergen-specific immunotherapy, which consists of administering increasing doses of an allergen over several months for desensitization. However, allergen-specific immunotherapy is limited by high levels of adverse reactions and poor long-term efficacy, particularly for food allergies.

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "About Neovacs
Listed on Euronext Growth Paris since 2010, Neovacs has become a major player in therapeutic vaccines targeting the treatment of autoimmune diseases, inflammatory diseases and certain cancers. Thanks to its innovative technology inducing a polyclonal immune response, potentially protected until 2032 by 4 families of patents, Néovacs focuses its clinical development efforts on IFNalpha Kinoide for the treatment of lupus and dermatomyositis. Neovacs also carries out preclinical work on other therapeutic vaccines for the treatment of autoimmune diseases, cancers, allergies and type 1 diabetes. The ambition of this "Kinoid approach" is to enable patients to better withstand life that would be more effective, well tolerated and very flexible in its administration. Néovacs is eligible for the PEA-PME plan.
For more information: http://neovacs.fr/ "data-reactid =" 23 ">About Neovacs
Listed on Euronext Growth Paris since 2010, Neovacs has become a major player in therapeutic vaccines targeting the treatment of autoimmune diseases, inflammatory diseases and certain cancers. Thanks to its innovative technology inducing a polyclonal immune response, potentially protected until 2032 by 4 families of patents, Néovacs focuses its clinical development efforts on IFNalpha Kinoide for the treatment of lupus and dermatomyositis. Neovacs also carries out preclinical work on other therapeutic vaccines for the treatment of autoimmune diseases, cancers, allergies and type 1 diabetes. The ambition of this "Kinoid approach" is to enable patients to better withstand life that would be more effective, well tolerated and very flexible in its administration. Néovacs is eligible for the PEA-PME plan.
For more information: http://neovacs.fr/

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "1 Sibilano: Nature Communication 2016; DOI: 10.1038 / ncomms13696 "data-reactid =" 24 ">1 Sibilano: Nature Communication 2016; DOI: 10.1038 / ncomms13696

2 Pawankar: Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organization Journal 2014 7:12.

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "contacts
NEOVACS – Corporate Communication and Investor Relations
Charlene Masson
Such. : +33 (0) 1 53 10 93 00
cmasson@Néovacs.com
relationship Press NewCap
Annie-Florence Rent
Such. : +33 (0) 6 88 20 35 59 / +33 (0) 1 44 71 00 12
afloyer@newcap.fr
Léa Jacquin
Tel: +33 (0) 6 58 14 84 66 / +33 (0) 1 44 71 20 41
ljacquin@newcap.fr"data-reactid =" 26 ">contacts
NEOVACS – Corporate Communication and Investor Relations
Charlene Masson
Such. : +33 (0) 1 53 10 93 00
cmasson@Néovacs.com
relationship Press NewCap
Annie-Florence Rent
Such. : +33 (0) 6 88 20 35 59 / +33 (0) 1 44 71 00 12
afloyer@newcap.fr
Léa Jacquin
Tel: +33 (0) 6 58 14 84 66 / +33 (0) 1 44 71 20 41
ljacquin@newcap.fr

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Press Release
"data-reactid =" 27 "> Press release

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = " This announcement is distributed by West Corporation on behalf of West Corporation customers.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NEOVACS via GlobeNewswire
"data-reactid =" 30 "> This announcement is distributed by West Corporation on behalf of West Corporation customers.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NEOVACS via GlobeNewswire

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "HUG # 2226356
"data-reactid =" 31 ">HUG # 2226356